Search | Médecins Sans Frontières Access Campaign

About us
About the Access Campaign

Some of our 2023 plans

Media room

Latest news

Jobs
Get Involved!
Sign up to stay updated and find out how you can get involved.

Email Address

Data protection consent

I want to receive emails from MSF and I have read and agree with the privacy policy.
Our work
COVID-19

Explainer: A bold proposal at the WTO by India and South Africa

Diabetes

Drug-resistant infections

HIV/AIDS

Hepatitis C

Hypertension

Patents and intellectual property

Pandemic prevention, preparedness and response

The Patent Oppositions Database

Research and development

Spotlight on: the Big Pharma double-dip

Transparency Matters: Clinical Trials Costs

Tropical and neglected diseases

Spotlight on: Snakebite

Tuberculosis

Vaccines

Explainer: COVID-19 vaccines - Recommendations for equitable access
Get Involved!
Sign up to stay updated and find out how you can get involved.

Email Address

Data protection consent

I want to receive emails from MSF and I have read and agree with the privacy policy.
Get involved
Campaign success stories

#NoMoreTears Johnson & Johnson Can you hear us?

A Fair Shot

Novartis 'Drop the case'

Trans-pacific Partnership (TPP)

Recent campaigns

Time for $5

No Patents in a Pandemic

Share the Tech - Save Lives
Take Action

Get Involved!
Sign up to stay updated and find out how you can get involved.

Email Address

Data protection consent

I want to receive emails from MSF and I have read and agree with the privacy policy.
Resources
Press releases

Statements

Letters

Opinion articles

Feature stories

Interviews

Blog

Newsletters

Publications

Research articles

Topic overview pages

Spotlight pages

Videos

Photo stories

Infographics

Events
Get Involved!
Sign up to stay updated and find out how you can get involved.

Email Address

Data protection consent

I want to receive emails from MSF and I have read and agree with the privacy policy.

Medicines shouldn’t be a luxury Take action

7 results found

Statement |

31 January 2014

MSF responds to news of pull out of neglected disease R&D by AstraZeneca

Tags Research and development malarianeglected diseasestuberculosis research and development (R&D) BayerPHARMACEUTICAL CompaniesAstraZeneca

Issue brief |

26 March 2013

Buruli Ulcer: Ending the Neglect of a Disease That Impacts the Young

Tags Intellectual property and tradeResearch and developmentTropical & neglected diseases Buruli ulcerco-infectionneglected diseases antiretroviral medicines World Health Organization

Thumbnail

Report |

12 December 2012

Medical Innovation for Neglected Patients

Tags Intellectual property and tradeResearch and development neglected diseases CEWGresearch and development (R&D) World Health Organization

Opinion article |

06 December 2012

Stuck in a time warp: WHO-brokered global R&D action plan shelved

Stuck in a time warp: WHO-brokered global R&D action plan shelved

Tags Intellectual property and tradeResearch and developmentTropical & neglected diseases neglected diseases CEWGresearch and development (R&D) DNDiWorld Health Organization

Press release |

03 December 2012

MSF response to the launch of the G-FINDER report

Tags Intellectual property and tradeResearch and developmentTropical & neglected diseases neglected diseasessleeping sicknessvisceral leishmaniasis (kala azar) research and development (R&D) World Health Organization

Press release |

30 January 2012

Combating Neglected Tropical Diseases: What is Still Missing

Tags Intellectual property and tradeResearch and developmentTropical & neglected diseases neglected diseasessleeping sickness Bill & Melinda Gates FoundationUSAIDWorld Health Organization

Letter |

13 January 2004

MSF letter to WHO Executive Board

Tags Research and development neglected diseasesHIV/AIDS World Health Organization